Looking ahead to the launch of its Neulasta (pegfilgrastim) biosimilar, Coherus BioSciences Inc. executives are encouraged by the US market for Amgen Inc.'s short-acting neutropenia drug Neupogen (filgrastim), where sales are split equally between the brand and the two biosimilars on the market – better penetration than most biosimilars in the US.
Coherus is preparing for a Jan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?